Search Bar & Filters
Found 13 Actively Recruiting clinical trials
Actively Recruiting
Researchers are evaluating the long-term safety and tolerability of intermittent use of elismetrep for treating acute migraine attacks. This Phase 3 study compares two doses of elismetrep, 10 mg and 20 mg, to understand their safety profiles over an average of one year. The study involves adult participants who have previously used elismetrep in an acute treatment trial and met compliance requirements. Participants are randomly assigned to receive either 10 mg or 20 mg of elismetrep taken orally during migraine attacks. The study uses a triple-masked design to ensure unbiased results. The treatment period spans approximately one year, during which safety and adverse events are closely monitored. This includes tracking any adverse events leading to discontinuation or serious adverse events related to the study drug. During the study, participants will complete electronic diaries to record migraine episodes and medication use. They will also attend scheduled visits to assess safety and tolerability, including monitoring for adverse events. The research team will measure the proportion of participants experiencing treatment-emergent adverse events and serious adverse events through study completion. Participants are expected to use a personal smartphone to maintain study diaries and comply with study procedures throughout the study duration.
Actively Recruiting
Researchers are investigating the long-term effectiveness, safety, and tolerability of once-daily oral ASC30 compared to a placebo in adults with obesity or overweight and type 2 diabetes mellitus T2DM. This Phase III, global, randomized, double-blind, placebo-controlled study seeks to understand how different maintenance doses of ASC30 impact these participants over time. Participants will be randomly assigned to receive one of three doses of oral ASC30 tablets or matching placebo tablets once daily. The study compares these groups to evaluate the effects of ASC30 on weight and metabolic health over a 72-week period. Treatment is administered daily by mouth throughout the study. During participation, individuals will undergo regular assessments including measurements of body weight, blood sugar control HbA1c and fasting glucose, blood pressure, cholesterol, triglycerides, insulin levels, waist circumference, and body mass index. The main outcome is the percent change in body weight from the start to week 72. Safety and tolerability will be closely monitored, and the entire study duration spans about 72 weeks from baseline to final evaluation.
Actively Recruiting
Researchers are studying chronic migraine, a condition causing moderate to severe headaches often on one side of the head, sometimes with nausea, vomiting, and sensitivity to light or sound. This trial evaluates how well the medicine atogepant works compared to a placebo in preventing chronic migraine in participants aged 12 to 17 years. The study also monitors adverse events to assess safety. Participants will be randomly assigned to receive either oral atogepant tablets or placebo once daily for 12 weeks. This double-blind study means neither the participants nor the doctors know who receives the medicine or placebo. Following the treatment, participants will be observed for an additional 4 weeks. During the study, participants will visit hospitals or clinics regularly for assessments. They will complete daily diaries, undergo medical evaluations, blood tests, side effect checks, and questionnaires. The main outcomes include tracking adverse events and changes in monthly migraine days, along with measures of headache days, medication use, and quality of life over approximately 16 weeks.
Actively Recruiting
Researchers are studying WIN378, a long-acting medicine, in adults with moderate to severe chronic obstructive pulmonary disease COPD. WIN378 targets a protein called TSLP that causes lung inflammation and may influence COPD symptoms and control. This Phase 2a trial aims to find the right dose by assessing safety, how the body processes the medicine, and its effects on markers of inflammation, lung function, and disease control. Participants will receive subcutaneous injections of WIN378 at different doses or a placebo over a 24-week treatment period while continuing their usual COPD therapies. The study is randomized, double-blind, and placebo-controlled, ensuring a thorough comparison of effects. The treatment phase lasts 24 weeks, followed by monitoring up to 36 weeks for safety and drug concentration in the blood. During the study, participants will undergo lung function tests, blood tests, and exhaled breath analyses to assess inflammation and COPD control. Researchers will monitor vital signs, laboratory parameters, and any adverse events throughout the 36-week period. The trial also tracks the presence of antibodies against WIN378. Participants are involved in regular evaluations to help understand how the medicine works and its safety profile.
Actively Recruiting
This research aims to evaluate the safety and effectiveness of atogepant, a medication currently approved for adults, in treating episodic migraine in children aged 6 to 17 years. The study focuses on pediatric participants who experience moderate to severe migraines with symptoms such as throbbing head pain, nausea, and sensitivity to light and sound. Limited treatment options exist for this age group, so the trial investigates different doses of atogepant to address this need. Participants are divided into groups based on age and receive either a placebo or low or high doses of atogepant tablets once daily for 12 weeks. Children aged 6 to 11 first undergo an open-label pharmacokinetic substudy to determine the appropriate dose before the double-blind treatment period. After the initial 12 weeks, participants either have a follow-up visit 4 weeks after their last dose or can continue receiving atogepant for an additional 52 weeks in an extension study. Throughout the study, participants attend regular visits at hospitals or clinics for medical assessments, blood tests, and questionnaires to monitor the effects of treatment and check for side effects. The main outcomes measured include changes in monthly migraine days and safety through adverse event tracking. The study plans to enroll about 450 children worldwide, with comprehensive monitoring over the treatment and follow-up periods.
Actively Recruiting
Researchers are evaluating the safety, tolerability, and effectiveness of AP306 at fixed doses in adults with hyperphosphatemia who are undergoing maintenance hemodialysis. Hyperphosphatemia is a common complication in advanced chronic kidney disease and is linked to increased risks of cardiovascular problems, fractures, and mortality, especially in dialysis patients. This randomized, double-blind, placebo-controlled study aims to better understand how well AP306 works to lower phosphate levels in this population. Participants will receive AP306 in varying doses, taken orally either twice or three times daily, or a placebo over an 8-week treatment period. The study includes several cohorts with different fixed dose regimens of AP306 or placebo. Treatment is given daily, and the study compares the ability of AP306 to lower serum phosphate compared to placebo. During the study, participants will be regularly assessed for phosphate levels and other safety measures. Researchers will monitor serum phosphate reduction, the proportion of participants reaching target phosphate levels, and time to response while ensuring tolerability and safety. The study is expected to last approximately 8 weeks of treatment with ongoing monitoring to evaluate the drugs effects and participant well-being.
Actively Recruiting
Researchers are evaluating the effectiveness, safety, and tolerability of elismetrep compared with a placebo for treating acute migraine attacks. This randomized, double-blind, phase III trial is conducted at multiple outpatient centers and sponsored by TriGemX Bio, Inc. The study focuses on adults aged 18 to 75 years who experience moderate to severe migraines lasting 4 to 72 hours, with a history of at least 2 but no more than 10 migraine attacks per month. Participants are randomly assigned to one of three groups elismetrep 10 mg, elismetrep 20 mg, or placebo. All treatments are taken orally during a migraine attack. The trial uses a parallel study design and is triple-blinded to ensure unbiased results. The main study period extends until February 2027, with participants monitored for responses two hours after dosing. During the study, participants will complete questionnaires and use an electronic diary on their smartphones to track migraine symptoms and treatment effects. Researchers will assess outcomes such as pain freedom, relief from bothersome symptoms, and functional disability at two hours post-dose. Additional evaluations include monitoring for adverse events up to eight days after dosing. Participants must follow the study schedule and complete all trial procedures to help assess elismetreps potential as an acute migraine treatment.
Actively Recruiting
Researchers are evaluating the safety, tolerability, pharmacodynamics, and efficacy of multiple ascending doses of the investigational drug CNP-103 in people aged 12 to 35 who have recently been diagnosed with Stage 3 Type 1 Diabetes within the last 6 months. This Phase 1b2a trial aims to understand how CNP-103 works and its effects in this population over about 393 days. Participants will receive three intravenous doses of CNP-103 at varying amounts 100 mg, 300 mg, or 600 mg on Days 1, 8, and 90. The study includes an initial Screening Period lasting 28 days, followed by a 90-day Treatment Period with dosing, and then a Post-Dose Evaluation phase lasting 275 days to monitor participants after treatment. Dosing for the Expansion Cohort will be based on results from the earlier Escalation Phase. During the study, participants will undergo assessments including safety and immune safety monitoring from Day 1 through Day 365. Researchers will collect data on how participants tolerate the treatment, any side effects, and immune responses. Participants will be monitored regularly throughout the nearly 13-month study period, including visits for drug administration, laboratory tests, and evaluations to measure the study outcomes and ensure safety.
Actively Recruiting
Researchers are evaluating the efficacy, safety, and tolerability of PL-14 Allergy Blocker compared to saline spray in adults with Seasonal Allergic Rhinitis SAR, a common condition causing symptoms like sneezing, nasal congestion, and itching triggered by airborne allergens. PL-14 Allergy Blocker is a drug-free intranasal hydrogel designed to form a mechanical barrier on the nasal lining to reduce allergen contact. This prospective, randomized, single-blind study plans to enroll up to 120 participants at multiple sites in the United States. Participants with a history of seasonal allergic rhinitis will first undergo a treatment-free run-in period, then be randomly assigned to self-administer either PL-14 Allergy Blocker or Ayr4 Saline Nasal Mist for up to 30 days. The study focuses on comparing these two devices to assess their effects on nasal allergy symptoms, quality of life, use of rescue medications, and symptom-free days. The active treatment period primarily covers the first 14 days, with continued assessments throughout the 30-day administration. During the study, participants will complete symptom scoring questionnaires, quality of life assessments, and record medication use. Safety will be monitored through adverse event tracking, nasal examinations, and evaluations of local tolerability. Participants will attend multiple visits over approximately 37 days, including screening, treatment, and follow-up phases, allowing researchers to measure the daily reflective Total Nasal Symptom Score and overall impact on allergy symptoms and safety.
Actively Recruiting
Researchers are evaluating whether using ultrasound imaging inside blood vessels during minimally invasive treatment of leg arteries improves outcomes for patients with symptomatic peripheral artery disease PAD classified as Rutherford class 2-5. This prospective, multicenter randomized controlled trial in the U.S. aims to compare clinical results between ultrasound-guided and standard angiography-guided interventions. The study is led by the Baylor Research Institute and focuses on lower extremity arterial disease affecting several specific artery locations. Participants will receive one of two treatments either intravascular ultrasound IVUS guidance during their endovascular intervention or a standard angiographic-guided procedure without IVUS. The IVUS is used before and after procedures like atherectomy, balloon angioplasty, or stent placement to guide treatment. The trial follows participants through these treatments to assess outcomes over time. During the study, participants will be monitored for clinical success and functional improvements using questionnaires and classifications over 12 months, with primary patency assessed at 6 months. Researchers will also evaluate technical and procedural success during the initial procedure, survival without amputation, the need for repeat interventions, and cost effectiveness. The total study duration extends to July 2028, with ongoing assessments to measure the impact of ultrasound guidance on treatment results.
1-10 of 13
1